CAMBRIDGE, Mass. and BERKELEY, Calif., June 20,
2024 /PRNewswire/ -- The Board of Directors of Regel
Therapeutics, a gene regulation company, announced that
Stephen J. Farr, PhD, begins today
as Chief Executive Officer (CEO).
Dr. Farr served as President and CEO of Zogenix from 2015 until
its acquisition by UCB in 2022. He transformed Zogenix into a
leading rare disease company, highlighted by the approval of
FINTEPLA in the US, Europe and
Japan. Dr. Farr initially served
as Zogenix's President and Chief Operating Officer since its
founding in 2006. Previously, Dr. Farr was Sr. Vice President
and Chief Scientific Officer at Aradigm Corp. From 1986
to 1995, Dr. Farr held tenured academic positions at Cardiff University, United Kingdom, concentrating in advanced drug
delivery and biopharmaceutics.
"We are excited to have Steve lead Regel Therapeutics and
believe that his vision and experience will build a strong team
focused on patient outcomes," said Dr Megan
McGill, Regel's interim CEO. Orrin
Devinsky, managing partner of PhiFund, which funded Regel's
seed round, added, "Steve Farr is
among the most respected leaders in biotech, he has the unique
ability to understand and connect with rare disease communities and
drive drug development to meet patient needs. We have the utmost
confidence in Steve and look forward to the next chapters in
Regel's future."
"I am thrilled to join Regel, a company that has pioneered
cell-specific gene control," said Dr. Farr. "Regel has a powerful
yet elegant scientific approach to cure genetic disorders that lack
disease modifying therapies. The talented and
passionate team have made key scientific innovations to
regulate gene expression to restore normal cellular functions.
Regel's pipeline includes proprietary programs as well as a
research collaboration with Sarepta Therapeutics."
Dr. Farr is on the board of directors of Mahzi Therapeutics, a
preclinical company focused on developing treatments for
under-served rare genetic neurodevelopmental disorders. He is also
co-founder and CEO of Ataraxia Therapeutics, a seed-stage company
discovering small molecule therapeutics for a novel CNS
target. Previously, he was a board member at Tevard
Biosciences, a preclinical company developing tRNA based
therapeutics to treat rare genetic diseases and director
at SteadyMed, Inc (NASDAQ: STDY) until its acquisition by
United Therapeutics.
About Regel Therapeutics
Regel's T3 platform combines a deactivated CRISPR system to bind
precise regions of DNA with proprietary regulatory elements to
activate or repress gene expression in highly specific cell
populations. In multiple animal models of genetic diseases, this
has produced efficient and permanent restoration of normal gene
expression exclusively in disease-affected cells. Regel is poised
to become first-in-class therapeutic intervention to transform the
lives of patients with severe genetic diseases. Regel operates in
both Berkeley, CA and in
Cambridge, MA. For more
information, see www.regeltherapeutics.com.
View original
content:https://www.prnewswire.com/news-releases/regel-therapeutics-appoints-stephen-j-farr-as-new-chief-executive-officer-302176097.html
SOURCE Regel Therapeutics Inc.